Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin.
Vanwert AL
,
Srimaroeng C
,
Sweet DH
.
???displayArticle.abstract???
Carboxyfluoroquinolones, such as ciprofloxacin, are used for the treatment of numerous infectious diseases. Renal secretion is a major determinant of their systemic and urinary concentration, but the specific transporters involved are virtually unknown. In vivo studies implicate the organic anion transporter (OAT) family as a pivotal component of carboxyfluoroquinolone renal secretion. Therefore, this study identified the specific renal basolateral OAT(s) involved, thereby highlighting potential sources of carboxyfluoroquinolone-drug interactions and variable efficacy. Two heterologous expression systems, Xenopus laevis oocytes and cell monolayers, were used to determine the roles of murine and human renal basolateral mOat1/hOAT1 and mOat3/hOAT3. Ciprofloxacin was transported by mOat3 in both systems (K(m) value, 70 +/- 6 microM) and demonstrated no interaction with mOat1 or hOAT1. Furthermore, ciprofloxacin, norfloxacin, ofloxacin, and gatifloxacin exhibited concentration-dependent inhibition of transport on mOat3 in cells with inhibition constants of 198 +/- 39, 558 +/- 75, 745 +/- 165, and 941 +/- 232 microM, respectively. Ciprofloxacin and gatifloxacin also inhibited hOAT3. Thereafter, in vivo elimination of ciprofloxacin was assessed in wild-type and Oat3 null mice [Oat3-/-]. Oat3-/- mice exhibited significantly elevated plasma levels of ciprofloxacin at clinically relevant concentrations (P < 0.05, male mice; P < 0.01, female mice). Oat3-/- mice also demonstrated a reduced volume of distribution (27%, P < 0.01, male mice; 14%, P < 0.01, female mice) and increased area under the concentration-time curve (25%, P < 0.05, male mice; 33%, P < 0.01, female mice). Female Oat3-/- mice had a 35% (P < 0.01) reduction in total clearance of ciprofloxacin relative to wild type. In addition, putative ciprofloxacin metabolites were significantly elevated in Oat3-/- mice. The present findings indicate that polymorphisms of and drug interactions on hOAT3 may influence carboxyfluoroquinolone efficacy, especially in urinary tract infections.
Aslamkhan,
The flounder organic anion transporter fOat has sequence, function, and substrate specificity similarity to both mammalian Oat1 and Oat3.
2006, Pubmed,
Xenbase
Aslamkhan,
The flounder organic anion transporter fOat has sequence, function, and substrate specificity similarity to both mammalian Oat1 and Oat3.
2006,
Pubmed
,
Xenbase
Aslamkhan,
Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells.
2003,
Pubmed
,
Xenbase
Bleasby,
Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6).
2005,
Pubmed
,
Xenbase
Burckhardt,
Transport of cimetidine by flounder and human renal organic anion transporter 1.
2003,
Pubmed
,
Xenbase
Cihlar,
The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.
1999,
Pubmed
,
Xenbase
Erdman,
The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics.
2006,
Pubmed
Foote,
Effects of probenecid and cimetidine on renal disposition of ofloxacin in rats.
1998,
Pubmed
Gasem,
Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever.
2003,
Pubmed
Gellert,
Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.
1977,
Pubmed
Gogos,
Penetration of ciprofloxacin into human cerebrospinal fluid in patients with inflamed and non-inflamed meninges.
1991,
Pubmed
Groves,
Sex differences in the mRNA, protein, and functional expression of organic anion transporter (Oat) 1, Oat3, and organic cation transporter (Oct) 2 in rabbit renal proximal tubules.
2006,
Pubmed
Höffken,
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
1985,
Pubmed
Hsieh,
The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding.
1998,
Pubmed
Ito,
Transepithelial transport of levofloxacin in the isolated perfused rat kidney.
2000,
Pubmed
Jaehde,
Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.
1995,
Pubmed
Jones,
Microbiology of newer fluoroquinolones: focus on respiratory pathogens.
2002,
Pubmed
Joos,
Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine.
1985,
Pubmed
Lipsky,
Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections.
1999,
Pubmed
Ljubojevic,
Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibition.
2004,
Pubmed
Martin,
Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide.
1996,
Pubmed
Matsuo,
Transport of levofloxacin in the OK kidney epithelial cell line: interaction with p-aminohippurate transport.
2001,
Pubmed
Meyerhoff,
US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax.
2004,
Pubmed
Ohtomo,
Transport of levofloxacin in a kidney epithelial cell line, LLC-PK1: interaction with organic cation transporters in apical and basolateral membranes.
1996,
Pubmed
Okano,
Interaction of ofloxacin with organic cation transport system in rat renal brush-border membranes.
1990,
Pubmed
Okuda,
Interactions of fluoroquinolone antibacterials, DX-619 and levofloxacin, with creatinine transport by renal organic cation transporter hOCT2.
2006,
Pubmed
Schnabolk,
Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20).
2006,
Pubmed
,
Xenbase
Shimada,
Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans.
1983,
Pubmed
Siefert,
Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys.
1986,
Pubmed
Sugino,
Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.
1977,
Pubmed
Sweet,
Basolateral localization of organic cation transporter 2 in intact renal proximal tubules.
2000,
Pubmed
,
Xenbase
Sweet,
Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney.
1997,
Pubmed
,
Xenbase
Sweet,
Localization of an organic anion transporter-GFP fusion construct (rROAT1-GFP) in intact proximal tubules.
1999,
Pubmed
,
Xenbase
Sweet,
Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice.
2002,
Pubmed
,
Xenbase
Sweet,
Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient.
2003,
Pubmed
,
Xenbase
Tahara,
A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters.
2005,
Pubmed
Ullrich,
Bisubstrates: substances that interact with both, renal contraluminal organic anion and organic cation transport systems. II. Zwitterionic substrates: dipeptides, cephalosporins, quinolone-carboxylate gyrase inhibitors and phosphamide thiazine carboxylates; nonionizable substrates: steroid hormones and cyclophosphamides.
1993,
Pubmed
Vanwert,
Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G.
2007,
Pubmed
VanWert,
Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates.
2008,
Pubmed
Wagenlehner,
Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.
2006,
Pubmed
Warren,
Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).
1999,
Pubmed
Youngblood,
Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney.
2004,
Pubmed
,
Xenbase
Zeiler,
Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay.
1987,
Pubmed
